Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Mol Cancer Res. 2013 Feb 1;11(4):418–426. doi: 10.1158/1541-7786.MCR-12-0518

Figure 2. Specific ablation of EpCAM decreases IL-8 expression.

Figure 2

(A-D) MCF-7, MDA-231 and CA1a breast cancer cell lines were transduced with lentiviral shRNA constructs targeting EpCAM (shUTR) or an irrelevant nucleotide sequence (shSCR). Stably transduced cells were subsequently analyzed for EpCAM expression by qRT-PCR (A), and protein immunoblot (B). IL-8 expression was measured by RT-PCR (C) and ELISA (D). For the ELISA assay, transduced cells were seeded onto 6-well plates, and conditioned media was collected after 24 hrs. (E, F) Transduced breast cancer cells were rescued with empty vector (pcDNA) or an EpCAM construct resistant to RNA interference at the indicated doses. Increasing doses of the EpCAM construct resulted in a dose-dependent increase in EpCAM expression as measured by protein immunoblot (E), and IL-8 expression as measured by ELISA (F).Asterisks indicate significance at P value <0.05 when compared to control.